Current dilemmas and controversies in allergic contact dermatitis to ophthalmic medications

Clinics in Dermatology

Volumn 29, Issue 3, 2011, Pages 295-299

  Novitskaya, Elena S ^a   Dean, Simon J ^b   Craig, Jennifer P ^b   Alexandroff, Anton B ^c  

^a PETERBOROUGH CITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c LEICESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS ACTING ON THE EYE; ANTIGLAUCOMA AGENT; APRACLONIDINE; BEFUNOLOL; BENZALKONIUM CHLORIDE; BETAXOLOL; BRIMONIDINE; CARBONATE DEHYDRATASE INHIBITOR; CARTEOLOL; CHLORAMPHENICOL; CHLORBUTOL; CORTICOSTEROID; DICLOFENAC; DORZOLAMIDE; GENTAMICIN; INDOMETACIN; KETOROLAC; LATANOPROST; LEVOBUNOLOL; METIPRANOLOL; NEOMYCIN; PENICILLIN G; PHENYLMERCURY DERIVATIVE; PILOCARPINE; SODIUM METABISULFITE; THIOMERSAL; TIMOLOL; TOBRAMYCIN; UNINDEXED DRUG; VANCOMYCIN;

ALLERGIC CONJUNCTIVITIS; ARTICLE; CONTACT DERMATITIS; CYTOTOXICITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; EYE ALLERGY; EYE INFECTION; EYELID DERMATITIS; GLAUCOMA; HUMAN; PERIORBITAL CONTACT DERMATITIS; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; PRURITUS; RISK ASSESSMENT; SKIN ALLERGY; SYSTEMATIC REVIEW;

ADMINISTRATION, TOPICAL; ALLERGENS; CONJUNCTIVITIS, ALLERGIC; DERMATITIS, ALLERGIC CONTACT; FACIAL DERMATOSES; HUMANS; OPHTHALMIC SOLUTIONS;

EID: 79954564353     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2010.11.008     Document Type: Article

References (16)

1. Baudouin C. Allergic reaction to topical eyedrops. Curr Opin Allergy Clin Immunol 2005, 5:459-463.
2. Jappe U., Uter W., Menezes de Padua C.A., et al. Allergic contact dermatitis due to beta-blockers in eye drops: a retrospective analysis of multicentre surveillance data 1993-2004. Acta Derm Venereol 2006, 86:509-514.
3. Hong J., Bielory L. Allergy to ophthalmic preservatives. Curr Opin Allergy Clin Immunol 2009, 9:447-453.
4. Ventura M.T., Viola M., Gaeta F., et al. Hypersensitivity reactions to ophthalmic products. Curr Pharm Des 2006, 12:3401-3410.
5. Herbst R.A., Uter W., Pirker C., et al. Allergic and non-allergic periorbital dermatitis: patch test results of the Information Network of the Departments of Dermatology during a 5-year period. Contact Dermatitis 2004, 51:13-19.
6. Corazza M., Masieri L.T., Virgili A. Doubtful value of patch testing for suspected contact allergy to ophthalmic products. Acta Derm Venereol 2005, 85:70-71.
7. Feser A., Plaza T., Vogelgsang L., Mahler V. Periorbital dermatitis-a recalcitrant disease: causes and differential diagnoses. Br J Dermatol 2008, 159:858-863.
8. Kaur I.P., Lal S., Rana C., et al. Ocular preservatives: associated risks and newer options. Cutan Ocul Toxicol 2009, 28:93-103.
9. Garcia-Medina J.J., Garcia-Medina M., Zanon-Moreno V.C., et al. Conjunctival provocation test for the diagnosis of ocular hypersensitivity to chlorobutanol. Cornea 2007, 26:94-97.
10. Chaudhari P.R., Maibach H.I. Allergic contact dermatitis from ophthalmics: 2007. Contact Dermatitis 2007, 57:11-13.
11. Holdiness M.R. Contact dermatitis to topical drugs for glaucoma. Am J Contact Dermat 2001, 12:217-219.
12. Gross R.L., Pinyero A., Orengo-Nania S. Clinical experience with apraclonidine 0.5%. J Glaucoma 1997, 6:298-302.
13. Motolko M.A. Comparison of allergy rates in glaucoma patients receiving brimonidine 0.2% monotherapy versus fixed-combination brimonidine 0.2%-timolol 0.5% therapy. Curr Med Res Opin 2008, 24:2663-2667.
14. Loon S.C., Liew G., Fung A., et al. Meta-analysis of randomized controlled trials comparing timolol with brimonidine in the treatment of glaucoma. Clin Exper Ophthalmol 2008, 36:281-289.
15. Williams G.C., Orengo-Nania S., Gross R.L. Incidence of brimonidine allergy in patients previously allergic to apraclonidine. J Glaucoma 2000, 9:235-238.
16. Herbst R.A., Maibach H.I. Contact dermatitis caused by allergy to ophthalmic drugs and contact lens solutions. Contact Dermatitis 1991, 25:305-312.